Medtronic (MDT) Reports 9.9% Q4 Revenue Growth, UBS Upgrades Stock

Medtronic (NYSE: MDT) announced Q4 revenue of $9.8 billion, reflecting a 9.9% increase, while fiscal 2026 revenue reached $36.4 billion, up 8.4%. The company achieved its highest annual revenue growth in 10 years, driven by significant performance in its cardiac segment, with Cardiac Ablation Solutions revenue increasing by 78%. UBS upgraded Medtronic from Neutral to Buy, citing signs of a turnaround after several years of underperformance. This information is important for investors as it indicates potential renewed growth and improved prospects for Medtronic, factoring into decisions on stock valuation and investment strategies.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.